Remove 2019 Remove Cannabis Remove Epilepsy Remove Research and Development
article thumbnail

Thailand: Press Release Thailand Govt Pharma Organization “Pharmaceutical Organization, Department of Medical Cooperation, Research on Medical Marijuana Extracts For cancer patients with neurodegenerative epilepsy And nervous pain”

Cannabis Law Report

30 May 2019. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Press Release: Thailand Government Pharmaceutical Organization.

article thumbnail

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

Cannabis Law Report

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The CBD Market Bets Big on Pets in 2019 and Beyond

Cannabis Law Report

After all, CBD is only one of the hundreds of documented cannabinoids found in cannabis and hemp. Although research on CBD is still in its infancy, to date there have been dozens of studies with more on the horizon. Although research on CBD is still in its infancy, to date there have been dozens of studies with more on the horizon.

Pets 59
article thumbnail

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

Cannabis Law Report

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. 14th at 11:00 a.m.

article thumbnail

Marijuana Associated With Improvement in Symptoms Related to Autism, Finds Case Study

The Joint Blog

The study is titled A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extract as complementary therapy: A case report. For the study researchers studied the effects of marijuana extracts in a fifteen-year-old who suffered from autism, anxiety, and controlled epilepsy. ml twice daily.

article thumbnail

Use of Cannabis-based medicinal products: NICE guidelines

Cannabis Law Report

Cannabis-based medicinal products. NICE guideline [NG144] Published date: November 2019. Recommendations for research. Severe treatment-resistant epilepsy. Severe treatment-resistant epilepsy. 1.4 Severe treatment-resistant epilepsy. Tools and resources. Recommendations. Rationale and impact. Spasticity.

article thumbnail

UK’s MS Society Launches #ApprovedButDenied Campaign

Veriheal

The United Kingdom’s Multiple Sclerosis (MS) Society has taken a stand against restricted access to medical cannabis in the country. The society launched a campaign with the hashtag #ApprovedButDenied protesting the difficulty so many patients have faced attempting to obtain medical cannabis. ApprovedButDenied.